Cardiology clinics
-
Pulmonary arterial hypertension (PAH) is a recognized complication of congenital systemic to pulmonary arterial cardiac shunts. The prognosis of PAH in this situation is better than primary or other secondary forms of PAH. Our knowledge of the pathophysiology of PAH complicating congenital heart disease has evolved over the past decade. Despite differences in etiology and pathobiology, therapies that have proven successful for primary PAH may benefit this group of patients.
-
The role of surgery and radiofrequency current ablation for the treatment of tachycardias in patients with congenital heart disease The use of radiofrequency current application as a treatment strategy has stimulated a revolution in our understanding of tachycardia mechanisms. The extension of its use to patients with congenital heart defects and tachyarrhythmias has opened the door to new treatments with known success rates and known risks for mortality and morbidity. Antiarrhythmic surgery aims to dissect or excavate a responsible substrate and is especially worth considering if cardiac surgery is being undertaken for other reasons. ⋯ Despite the immense growth of knowledge and experience in recent years, there is still a need for more knowledge about the factors causing arrhythmogenesis and their interactions. Prospective and randomized studies are needed to show the most effective strategies to prevent arrhythmia-mediated death. The future of antiarrhythmic treatment will less be directed by the limitations of current interventional tools, which will be improved, and more by an evolutionary process in philosophy regarding the understanding of arrhythmogenesis in these patients as the basis for new concepts of arrhythmia prevention and treatment.